The pandemic hit the Silesian coal basin in southern Poland very strongly, the national rate remained relatively low compared to much of Western Europe.
“Today we are production,” Piotr Fic, a board member of biotechnology company Biomed Lublin, said at a press conference at Lublin Medical University in western Poland.
“Probably until the end of October, we will supply the drug for clinical trials,” he said.
Krzysztof Tomasiewicz of PSK1 Public Hospital in Lublin, one of the assignment participants, said: “Our expectations are high, positive and based on some experience. “
The company plans to produce an initial batch of 3,000 doses of the drug to be tested and said it would eventually produce between 30,000 and 40,000 doses, depending on the availability of enough plasma.
Convalescent plasma, the fluid in the blood complete with antibodies after illness, has been shown in small studies to treat COVID-19.
Researchers reported collecting about liters of plasma for initial production.
Biomed CEO Marcin Pirog said in a statement that Jastrzebska miners Spolka Weglowa (JSW), a company with five coal mines, deserved “special recognition” for their blood donations.